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Background: Policy developments in recent years have led to important changes in the level
of access to evidence-based psychological treatments. Several methods have been used to
investigate the effectiveness of these treatments in routine care, with different approaches to
outcome deﬁnition and data analysis. Aims: To present a review of challenges and methods
for the evaluation of evidence-based treatments delivered in routine mental healthcare. This
is followed by a case example of a benchmarking method applied in primary care. Method:
High, average and poor performance benchmarks were calculated through a meta-analysis of
published data from services working under the Improving Access to Psychological Therapies
(IAPT) Programme in England. Pre-post treatment effect sizes (ES) and conﬁdence intervals
were estimated to illustrate a benchmarking method enabling services to evaluate routine
clinical outcomes. Results:High, average and poor performance ES for routine IAPT services
were estimated to be 0.91, 0.73 and 0.46 for depression (using PHQ-9) and 1.02, 0.78 and 0.52
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for anxiety (using GAD-7). Data from one speciﬁc IAPT service exemplify how to evaluate
and contextualize routine clinical performance against these benchmarks. Conclusions: The
main contribution of this report is to summarize key recommendations for the selection of
an adequate set of psychometric measures, the operational deﬁnition of outcomes, and the
statistical evaluation of clinical performance. A benchmarking method is also presented, which
may enable a robust evaluation of clinical performance against national benchmarks. Some
limitations concerned signiﬁcant heterogeneity among data sources, and wide variations in ES
and data completeness.
Keywords: Benchmarking, primary care, depression, anxiety.
Introduction
In the last decade, two important streams of research evidence have come together resulting in
an important paradigm shift and transformation of mental healthcare. First, epidemiological
studies have drawn attention to the high prevalence, health, societal and economic impact of
depression and anxiety disorders (Das-Munshi et al., 2008; Kessler et al., 2003; McManus,
Meltzer, Brugha, Bebbington and Jenkins, 2009). Second, psychotherapy research has
progressively aligned itself to the evidence-based medicine movement, amassing empirical
support for the efﬁcacy of psychological interventions (Chambless et al., 1998). Consequently,
the dissemination of empirically supported treatments (EST) has been advocated by clinical
guidelines (National Institute for Health and Clinical Excellence, 2007a, b), which in turn
have led to changes in the organization of psychological services.
An example of this movement can be found in the Improving Access to Psychological
Therapies (IAPT) programme. This large-scale government funded initiative has been piloted
and implemented in England since 2008, organizing EST for depression and anxiety in a series
of progressively intensive stages of therapy – otherwise referred to as a stepped-care model
(Richards and Suckling, 2009). There is, however, debate in the ﬁeld about the “real world”
effectiveness of EST in these routine services and outside of the closely controlled conditions
of an efﬁcacy study. The argument about external validity, for example, suggests that the
results of clinical trials are not necessarily generalizable to ordinary healthcare populations
that present a range of co-morbidities and demographic factors that render them distinct to
research participants (Chambless and Ollendick, 2001; Franklin and DeRubeis, 2006). Others
have argued that delivering effective EST requires close adherence to protocols used in clinical
trials (Roth and Fonagy, 2004; Siev, Huppert and Chambless, 2009) and speciﬁc competences
(Roth and Pilling, 2007). In routine practice, treatment ﬁdelity is likely to vary from service to
service, and this may account for differences in clinical outcomes (Glover, Webb and Evison,
2010).
Therefore, the large-scale dissemination of EST in routine practice raises some important
questions. How do routine outcomes compare to those of efﬁcacy studies? How do we
measure outcomes in routine practice? How can we evaluate the outcomes of a routine
service compared to other similar services? The main objective of this paper is to discuss
some key challenges related to the measurement, deﬁnition and comparative analysis of
clinical outcomes. A second objective is to present a case example of how to deal with some
of these methodological challenges and evaluate the outcomes of a routine service against
national benchmarks and clinical trials. References and analyses focus on the English IAPT
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programme to contextualize the discussion and illustrate the application of benchmarking
methods.
Measuring, defining and comparing clinical outcomes
Selecting outcome measurement tools
With the psychotherapy research literature describing over 100 different patient reported
outcome measures, many with proven diagnostic validity and reliability (Wahl, Meyer, Löwe
and Rose, 2010), specifying a set of measures for a routine service can be challenging. A
second challenge is that routine services in primary care often see a heterogeneous group
of patients with multiple diagnoses. This introduces a tension between selecting diagnosis-
speciﬁc tools versus more general measures of improvement (e.g. overall psychological
distress, functioning or quality of life), or idiosyncratic measures that are internally valid
to the treatment of individual patients. Another challenge is the selection of a set of
measures that are acceptable to patients in terms of their content and length. Some important
considerations for the selection and application of outcome measures are summarized below,
based on outcomes research and clinical guidelines (Blais et al., 2012; McAleavey, Nordberg,
Kraus and Castonguay, 2012; Minami, Wampold, Serlin, Kircher and Brown, 2007; National
Screening Committee, 2003; Newnham and Page, 2010; NICE, 2011; Wahl et al., 2010).
• The selection of outcome measures from a pool of candidate tools should weigh up the
following features: (a) research evidence of robust validity and reliability; (b) research
evidence of acceptability to patients; (c) ease of administration and interpretation; (d)
cost of training and implementation; (e) availability in several languages and formats to
maximize accessibility; (f) the extent of published normative data to make comparative
research more feasible.
• An adequate set of measures should balance: (a) diagnosis-speciﬁc measures that are
matched to the service’s target population and inclusion criteria; (b) “higher level”
measures of functioning and/or quality of life; and (c) idiosyncratic measures that can
capture individualized patient goals and outcomes. Such a combination of measures may
render a good balance between reactivity (wide relevance to the treatment population) and
speciﬁcity (e.g. precision of disorder-speciﬁc measures to the symptoms of individuals)
(Minami et al., 2007). The number and length of measures should take into consideration
the potential time onus and burden on clinicians and patients.
• Collecting these measures at repeated intervals can signiﬁcantly maximize data
completeness (Richards and Suckling, 2009) and enables their utilization in providing live
feedback to patients and clinicians, which can in itself improve outcomes for some patients
(Shimokawa, Lambert and Smart, 2010).
• Repeated exposure to cognitive tests (such as memory or intelligence tests) can inﬂuence
performance through practice, and this is problematic when aiming to investigate the
inﬂuence of a speciﬁc intervention over and above the inﬂuence of so-called “practice
effects” (McCaffrey and Westervelt, 1995). In theory, it is possible that practice effects
and/or fatigue may ensue in a process of repeated psychological symptom measurement
(Larsen and Fredrickson, 1999). However, there is yet no convincing evidence that practice
4 J. Delgadillo et al.
or fatigue effects may undermine the validity of repeated outcome measurement outside of
the speciﬁc area of neuropsychological testing.
IAPT is an example of a large-scale programme using a speciﬁc set of measures that
meet many of the above criteria. It employs brief validated measures of depression and
anxiety (PHQ-9 and GAD-7; Kroenke, Spitzer, Williams and Löwe, 2010), which are publicly
available in several languages, and generally acceptable to patients in spite of criticisms by
health professionals (Dowrick et al., 2009). They are used at repeated measurement points,
alongside measures of functioning and adjustment, and several disorder-speciﬁc measures
that are more sensitive to individual cases (IAPT National Programme Team, 2011).
Defining improvement
Selecting an adequate set of measures then poses the challenge of deﬁning clinically
meaningful improvement (and deterioration). Most diagnostic measures are interpreted based
on normative cut-off scores that discriminate those respondents who are more or less likely
to meet criteria for a speciﬁc condition. For example, a score >10 on the PHQ-9 measure
used in the IAPT programme is considered to be indicative of major depression (Kroenke,
Spitzer and Williams, 2001). Hence, several outcome evaluations have estimated depression
improvement rates based on the numbers of patients with PHQ-9 scores >10 whose scores
reduced below this cutpoint after treatment (Clark et al., 2009; Glover et al., 2010; Richards
and Suckling, 2009). An important problem with this deﬁnition of improvement is that it
is particularly susceptible to “Type I error”, which occurs when cases with no meaningful
symptom change are assumed to have improved. One explanation is that this method does
not account for measurement error that may be due to inherent limitations in the precision
of the questionnaire. Another related explanation is that cases with marginal symptom
reductions are counted as “recovered”, when such small reductions may possibly be due to
natural ﬂuctuations or regression to the mean.1 A way to deal with this may be to use a
multidimensional approach that would involve triangulating two or more correlated measures
to enable a more holistic assessment of change (McAleavey et al., 2012). Clark et al. (2009),
for example, proposed a multidimensional method referred to as “IAPT recovery”. According
to this method, patients scoring above the clinical cut-off in a depression (PHQ-9) or anxiety
measure (GAD-7) at baseline will have “recovered” if their post-treatment scores are below
the cut-offs for both measures. Although this is a stricter way to deﬁne outcomes, the
possibility of Type I error still remains, particularly if small changes in both measures are
due to regression to the mean.
A more robust way to minimize Type I error is to employ a reliable change index (RCI),
which is a statistic used to evaluate whether observed changes on a scale are statistically
reliable and not solely due to chance (Jacobson and Truax, 1991). The RCI is essentially a
certain number of points on a scale above which observed changes are considered statistically
reliable. For example, Richards and Borglin (2011) propose that a minimum reduction of 6
points in the PHQ-9 measure would be indicative of reliable improvement. Taken together,
1Regression to the mean is a phenomenon where extreme measures are statistically more likely to reduce closer to
the mean at subsequent measurement points.
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the RCI and the diagnostic cut-off score can help to deﬁne reliable and clinically signiﬁcant
improvement, which has been recommended as a robust method for assessing recovery in
psychological interventions (Evans, Margison and Barkham, 1998; Jacobson and Truax, 1991;
McMillan, Richards and Gilbody, 2010).
There are, however, some disadvantages to using a dichotomous deﬁnition of improvement
(e.g. recovered vs. not recovered). In primary care, not all patients will necessarily meet
criteria for a signiﬁcant mental disorder; in fact, clinical guidelines advocate offering
evidence-based treatments to people with mild or sub-threshold depression and anxiety
(NICE, 2007a, b). Therefore, a dichotomous outcome deﬁnition does not account for symptom
changes in patients with mild disorders. Although only limited symptom reductions can
be expected in patients with sub-clinical symptoms, it is possible that such patients may
deteriorate, and therefore rates of reliable deterioration should also be reported if dichotomous
outcome deﬁnitions of recovery are adopted. Another limitation is that focusing only on
“recovery” fails to recognize signiﬁcant symptom changes for patients who may still meet
criteria for a common mental disorder but may feel considerably better or less severely
disabled.
An alternative approach employed in many psychotherapy clinical trials and meta-analyses
is to measure symptom changes using effect sizes (ES), a summary statistic that denotes the
magnitude of changes observed in any given measure. ES account for all cases in a given
sample, regardless of their diagnostic status at baseline, making it an inclusive measure
for service level data. ES account for symptom changes in either direction: improvement,
deterioration or no change. ES can also be easily interpreted using conventional deﬁnitions
of small (around .20), moderate (.50) and large (.80) effects (Cohen, 1998). Furthermore,
given their prominence in the research literature, ES enable wide comparisons across studies.
In summary, each of these outcome deﬁnition methods has its particular advantages, and
therefore a comprehensive investigation of outcomes could combine ES and rates of reliable
and clinically signiﬁcant improvement (RCSI).
Comparing and evaluating clinical outcomes
A number of methods have been used to investigate the effectiveness of evidence-based
treatments applied in routine mental health care. One method is “benchmarking”, which
consists of the statistical comparison of routine clinical outcomes against those of clinical
trials as high efﬁcacy benchmarks, or against ES observed in control or “no treatment” groups
as lower benchmarks for no signiﬁcant treatment effects (Lueger and Barkham, 2010; Minami,
Serlin, Wampold, Kircher and Brown, 2008; Weersing and Weisz, 2002). Minami et al. (2007,
Minami, Serlin et al., 2008; Minami, Wampold et al., 2008) have considerably advanced
this method by proposing standard procedures to calculate ES and to statistically compare
these to published benchmarks. For example, using meta-analytic methods they estimated
an ES of 0.15 for “no treatment” control groups of depressed patients, and argue that ES
within a critical value (equivalent to 1/5 of a standard deviation) above this estimate may
not be signiﬁcantly different. Similarly, they estimated an efﬁcacy benchmark of 0.79 based
on clinical trials for depression; and reason that ES observed in routine practice within the
critical value (1/5 of a standard deviation below or above) should be considered clinically
comparable.
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Benchmarking methods have been employed in published evaluations of IAPT services
(Clark et al., 2009; Glover et al., 2010; Richards and Suckling, 2009). The two earlier studies
reﬂect the effectiveness of pilot services termed “demonstration sites”, which reported large
clinical ES (between 1.06 and 1.38 for depression; 0.98 to 1.41 for anxiety) comparable to
those of published randomized controlled trials of similar interventions. The Glover et al.
(2010) report describes the clinical outcomes of the ﬁrst year of implementation of the IAPT
programme in 30 routine services termed “roll-out” sites, which suggests that clinical ES are
largely variable across sites (ranging from as low as 0.38 and as high as 1.09). However,
methods differ across these reports with regards to aggregation of data, calculation of ES, and
deﬁnition of outcomes. Furthermore, outcomes are compared to those of clinical trials, but no
systematic comparisons to lower benchmarks are made.
In the absence of a consistent benchmarking method for routine services, conventional
league table ranking methods have been used as a means of evaluating the performance of
services against one another. An example is found in the National Audit for Psychological
Therapies report (Royal College of Psychiatrists, 2011). This report analyzed data for over 100
services that had available pre and post-treatment outcome measures. Services were ranked
using percentiles and quartiles according to the observed rate of cases meeting criteria for
recovery based on conventional cut-offs on several diagnostic measures. Although this is a
common method used to rank services, it is limited by its lack of attention to measurement
error, and it also ignores the possibility that outcomes may not necessarily be statistically
different between services that are ranked as more or less effective. The actual recovery
estimates for a service ranked as below average (e.g. quartile below 50%) may not be
signiﬁcantly different to that of an “above average service” (e.g. above 50% percentile), and
apparent differences may be simply due to variations in sample size or data completeness.
More importantly, such methods do not provide any insight into the factors that may account
for differential performance between services. Differences in socio-economic status, for
example, have been shown to be associated with outcomes in naturalistic treatment settings,
with patients paying for private insurance showing modestly higher improvement (Blais
et al., 2012). Other areas of healthcare have advanced sophisticated benchmarking methods
that adjust for differences in case-mix, which may partly account for outcome differences
between services (e.g. Orkin, 2010). To the best of our knowledge such methods have not yet
been used in the evaluation of routine psychological services.
Case example of a benchmarking method
In the following section, we present an example of how to generate benchmark values against
which a speciﬁc service’s performance can be evaluated, using published data from the IAPT
programme.
Outcome measures used in benchmark calculations
The measures used for the calculation of benchmark values were restricted to the PHQ-9 and
GAD-7, since these measures are routinely and widely collected as part of a national dataset
for patients accessing IAPT services in England, reasonably enabling broad comparisons for
clinical outcomes aggregated at service level.
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The PHQ-9 is a 9-item measure of depression based on the Diagnostic and Statistical
Manual (DSM-IV) diagnostic criteria for major depressive disorder (Kroenke et al., 2001).
Scores range from 0 to 27, with higher scores indicating greater severity of depression, and
a score of 10 or above on this measure has been proposed as indicative of meeting criteria for
major depression (Gilbody, Richards and Barkham, 2007; IAPT National Programme Team,
2011; Kroenke et al., 2001).
The GAD-7 is a 7-item measure originally developed as a screen for Generalized Anxiety
Disorder (Spitzer, Kroenke, Williams and Löwe, 2006). The capacity of the GAD-7 to detect
other anxiety disorders, including social phobia, post-traumatic stress disorder and panic
disorder, has also been established (Kroenke, Spitzer, Williams, Monahan and Löwe, 2007).
Scores range from 0 to 21, with higher scores indicating greater severity of symptoms; a score
above 8 is indicative of an anxiety disorder.
Method
Outcome benchmarks were estimated using data published by Glover et al. (2010), reporting
ES for 30 “roll-out” sites that applied the IAPT programme in routine practice during the
ﬁrst year of implementation in England. Our strategy was to generate high, medium and low
performance estimates based on the observed outcomes in a national sample of services. We
then estimated clinical outcomes using contemporaneous data from one routine IAPT site
in Leeds, and used this as a case example to illustrate how to evaluate one service against
national benchmarks.
The calculations of benchmark values were based on cases in the datasets that: (a) had
received at least two appointments, the ﬁrst being a pre-treatment suitability assessment
contact and the second being a treatment session; (b) had pre-treatment measures available
that could be taken as a baseline; and (c) had been discharged from treatment. Using intent-
to-treat principles, this included patients who may have dropped out in addition to those who
completed treatment; the last observed measure was taken as a post-treatment rating. Pre-
post treatment uncontrolled ES and conﬁdence intervals were calculated using the formulas
proposed by Minami, Serlin et al. (2008, pp. 517–520); this is a comparable measure to
Cohen’s d (Cohen, 1998), computed for repeated measures and weighted by sample size.
An important innovation introduced by Minami and colleagues is the calculation of 95%
conﬁdence intervals with reference to “critical values” that are equivalent to 1/5 of a standard
deviation. These authors reason that when comparing clinical effect sizes against efﬁcacy
benchmarks, statistically signiﬁcant differences may not always be clinically important. The
“critical value” factored into their conﬁdence interval calculations ensures that comparisons
between routine clinical outcomes and performance benchmarks should be statistically
and clinically signiﬁcant. Following these authors, standardized ES were aggregated using
conventional meta-analytic methods and forest plots to calculate measure-speciﬁc estimates
for all of the 30 IAPT roll-out sites into a summary ﬁgure for depression (PHQ-9) and another
for anxiety (GAD-7). We calculated “average” benchmarks based on the mean ES for all 30
sites. Next, we calculated “high” and “low” performance benchmarks based on pooled ES for
the four highest performing sites and four poorest performing sites. We selected four sites
because this number represented the bottom eighth and the top eighth of the 30 sites. PHQ-9
and GAD-7 ES for the Leeds site were then statistically compared to the benchmark estimates.
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Table 1. Leeds IAPT site data
Demographics n = 2891
Mean age (SD) 37.9 (13.1)
Female 64.3%
White British 88.9%
In employment 62.9%
Off work due to ill health 10.6%
Receiving state ﬁnancial support 16.9%
Referred by a GP 80.2%
Scoring in the clinical range in PHQ-9 measure (depression) 73.4%
Scoring in the clinical range in GAD-7 measure (anxiety) 80.2%
Prescribed psychotropic medication 45.3%
Mean therapy contacts (SD) 5.7 (3.9)
Outcome data Pre-treatment Post-treatment
PHQ-9 mean (SD) 14.1 (6.4) 8.9 (6.9)
GAD-7 mean (SD) 12.6 (5.3) 7.9 (5.9)
Notes: Based on all discharged cases with >2 contacts and available pre/post treatment data;
proportions could only be estimated for the subset of valid data records. GP = general medical
practitioner
As recommended in the preceding discussion, we calculated reliable and clinically
signiﬁcant improvement rates (RCSI; Jacobson and Truax, 1991) as an additional performance
indicator. This could only be estimated for the Leeds site, since we only had access to case-
level data for this service, and there is no reference to RCSI in Glover et al. (2010). Following
Richards and Borglin (2011), our deﬁnition of RCSI for depression required a patient with a
PHQ-9 >10 at baseline to have (a) reduced this score by at least 6 points and (b) to have a
post-treatment score < 10. For GAD-7, a score >8 was taken as a cut-off for a diagnosis of an
anxiety disorder, and RCSI required (a) a reduction of at least 5 points and (b) a post-treatment
score < 8.
Results
A brief contextual description of the Leeds site is presented ﬁrst, followed by a comparative
analysis of these data against national benchmark values. The Leeds IAPT site offers
evidence-based psychological therapy organized in a stepped-care model, following national
treatment guidelines (NICE 2007a, b, 2011). This service received referrals for 14,453 people
between the March 2009–2010 data collection period, 5783 of whom accessed therapy
following assessment. A total of 2891 cases that were discharged from the service at the
time of data collection had both pre and post-therapy outcome measures available, and were
included in data analysis (77% data completeness). Treatment options at the time of this study
included cognitive behavioural therapy (CBT), computerized CBT, brief guided self-help, and
psycho-education groups. Approximately 86% of patients were offered low intensity (step 2 in
the stepped-care model) treatment options with a mean duration of 4.8 (SD = 2.64) sessions.
Approximately 13% were offered high intensity CBT (step 3) with a mean duration of 9.9
(SD = 6.72) sessions, and less than 1%were referred to long-term psychotherapy in secondary
care (step 4). Table 1 describes basic demographic characteristics for the Leeds dataset, which
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are largely comparable to the data reported in the benchmark report cited above in terms of
gender, ethnic mix, employment status and diagnostic characteristics.
Forest plots of depression (PHQ-9) and anxiety (GAD-7) ES are presented in Figures 1
and 2, which represent the clinical performance of 30 IAPT roll-out sites and the Leeds
site for comparison. These ﬁgures also overlay estimated high, average and low performance
benchmarks. Considerable variation in sample size and ES across sites was evident, as well
as varying degrees of precision in these calculations, denoted by the width of conﬁdence
intervals (which include critical values weighted by sample size). Amongst the 30 roll-out
sites, the Leeds site’s ES were ranked in 8th place, or ﬁrst quartile (25.8%) taking n = 31 as
denominator. The aggregated data estimates based on which ES were calculated can be found
in the Glover et al. (2010) report and are therefore not presented in this paper. The relevant
estimates for Leeds PCMHS are in Table 1.
Estimates of heterogeneity of ES for roll-out sites were calculated using the Q test
(Cochran, 1954) and the related I2 statistic to provide a measure of the percentage of variation
across sites (Higgins, Thompson, Deeks and Altman, 2003). For depression (PHQ-9),
Q (29) = 313.5, I2 = 91%, p < .001; for anxiety (GAD-7), Q (29) = 369.8, I2 = 92%,
p < .001. All were highly signiﬁcant (p < .001) with I2 much higher than the 75% value
generally taken as an index of high variation, indicating large heterogeneity between sites.
Figure 3 provides a graphical summary of key performance indicators, using the Leeds
site data to illustrate the benchmarking of routine clinical outcomes. Vertical lines in this
graph represent the continuum of ES for PHQ-9, and GAD-7, with overlaid high, average and
low performance benchmarks for national services. The Leeds site’s ES for depression and
anxiety (PHQ-9 = 0.81 / GAD-7 = 0.90) were signiﬁcantly larger than low (0.46 / 0.52) and
average (0.73 / 0.78) benchmarks, but signiﬁcantly smaller than high level benchmarks (0.91 /
1.02). This was determined based on the null hypothesis that if the benchmark estimate
is contained within the conﬁdence intervals of the ES for the routine service, there is no
signiﬁcant difference between estimates (following Minami, Serlin et al., 2008). Furthermore,
the Leeds site’s ES were signiﬁcantly different to the “no treatment” lower level benchmark
(0.15 ES) proposed by Minami, Serlin et al. (2008), but not statistically different to the
efﬁcacy benchmark from clinical trials (0.79 ES). Finally, reliable and clinically signiﬁcant
improvement rates (RCSI) for the Leeds site were 42.2% for depression and 43.5% for
anxiety. These estimates were closely comparable to depression (41%) and anxiety (40%)
RCSI estimates reported by Richards and Borglin (2011) for the IAPT demonstration site.
Discussion
This paper presents a considered review of challenges and methods for the selection of
an adequate set of psychometric measures, the operational deﬁnition of outcomes, and the
statistical comparison and evaluation of clinical performance. This study used historical
outcome estimates available in the public domain; the intention was to exemplify a robust
method that could be employed to analyze more current datasets such as those generated
routinely by the English IAPT programme.
There are some limitations concerning the benchmarking method presented in this paper.
Data quality and completeness appeared to vary considerably across IAPT roll-out sites, with
a wide range of completion rates ranging from 21.4% to 100% (Glover et al., 2010). Data
completion rates will likely lead to biases in the outcome data, as noted by Clark et al.
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R14 n=1529 d=0.88 (0.82, 0.94)
R6 n=1552 d=0.91 (0.85, 0.96)
R4 n=956 d=0.95 (0.87, 1.02)
R28 n=641 d=0.95 (0.86, 1.04)
Depression effect sizes (PHQ-9)
Notes: Solid line = average benchmark (0.73); doed lines = low (0.46) and high (0.91) performance benchmarks 
Figure 1. Forest plot of PHQ-9 effect sizes (and 95% CI) for IAPT roll-out sites (R), and Leeds site
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R21 n=817 d=0.57 (0.49, 0.64)
R12 n=366 d=0.61 (0.49, 0.72)
R9 n=477 d=0.62 (0.52, 0.72)
R25 n=1255 d=0.66 (0.60, 0.72)
R10 n=448 d=0.68 (0.57, 0.78)
R13 n=148 d=0.69 (0.51, 0.87)
R27 n=1097 d=0.69 (0.63, 0.76)
R15 n=416 d=0.70 (0.59, 0.81)
R26 n=228 d=0.70 (0.56, 0.85)
R8 n=738 d=0.71 (0.63, 0.79)
R18 n=60 d=0.74 (0.45, 1.03)
R19 n=264 d=0.76 (0.62, 0.89)
R11 n=690 d=0.76 (0.67, 0.85)
R33 n=1474 d=0.76 (0.70, 0.82)
R23 n=1712 d=0.77 (0.72, 0.83)
R31 n=1733 d=0.78 (0.73, 0.84)
R16 n=808 d=0.80 (0.72, 0.88)
R5 n=1001 d=0.85 (0.77, 0.92)
R3 n=325 d=0.85 (0.72, 0.98)
R7 n=1140 d=0.89 (0.82, 0.96)
R36 n=1058 d=0.90 (0.83, 0.97)
R17 n=725 d=0.92 (0.83, 1.01)
R24 n=136 d=0.92 (0.72, 1.12)
R14 n=1534 d=0.92 (0.86, 0.99)
R6 n=1549 d=0.96 (0.90, 1.02)
R28 n=640 d=1.01 (0.91, 1.11)
R22 n=118 d=1.10 (0.87, 1.34)
R4 n=955 d=1.11 (1.03, 1.19)
      Anxiety effect sizes (GAD-7) 
 
Notes: Solid line = average benchmark (0.78); doed lines = low (0.52) and high (1.02) performance benchmarks 
Figure 2. Forest plot of GAD-7 effect sizes (and 95% CI) for IAPT roll-out sites (R), and Leeds site
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Valid n 0982 2891
Data completeness 77% 77%
n cases >= cutoff 2125 2320
%2.24 ISCR 43.5%
Figure 3. Benchmarking of key performance indicators for Leeds IAPT site
(2009). The very high degree of heterogeneity between sites in ES (over 90%) should also be
considered and researched. This may be due to the fact that sites in this historical dataset were
at very different stages of development and implementation, and may also relate to completion
rates mentioned above. However, the reasons for this high degree of variation will be complex
and we have merely highlighted some factors likely to account for this.
It is important that the performance of a service is not judged simply in terms of its
placement relative to the different benchmark values. Although mediation analyses were not
possible to present in this benchmarking report since case-level data were not available to do
this, it is noted that other authors have already described factors associated with differential
outcomes in IAPT services. For example, Gyani, Shafran, Layard and Clark (2011) argue that
variability in the performance of IAPT roll-out sites was related to differences in baseline
severity, proportions of patients stepped up to high intensity treatment, greater length of
treatment, and delivery of NICE recommended disorder-speciﬁc treatments for patients in
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high intensity therapy. In this context, the relative placement of the Leeds site in amongst the
benchmark values may be partly explained by its higher mean number of treatment sessions
and higher degree of treatment ﬁdelity2 at step 3 compared to the “average” IAPT site reported
in Glover et al. (2010).
Furthermore, as previously described, it is possible that the demographic and diagnostic
mix varies across services, and this may account for some differences in clinical effect.
Benchmarking methods that adjust for case-mix (e.g. accounting for baseline severity, socio-
economic status, chronic health and comorbidity) may be developed as these data emerge in
the future. Future benchmarking developments could also compare the relative ES estimates
obtained with disorder-speciﬁc measures versus those obtained with more general distress
measures. Clearly all of these factors should be considered when evaluating the effectiveness
of a service and one of the concerns of benchmarking is that it could be used in a simplistic
way, ignoring contextual, diagnostic and population factors such as those described above.
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